Improved Lipid Profiles and Maintenance of Virologic Control in Heavily Pretreated HIV-Infected Patients Who Switched from Stavudine to Tenofovir Treatment
Open Access
- 1 January 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (1) , 145-147
- https://doi.org/10.1086/498516
Abstract
A retrospective chart analysis of 66 human immunodeficiency virus type 1 (HIV-1)— infected patients whose treatment was switched from stavudine to tenofovir without any other treatment changes was conducted. The mean total cholesterol values decreased significantly within 3 months after the tenofovir substitution and remained significantly less than baseline values during 18 months of follow-up (mean decrease, 36 mg/dL; P =.002). Regimens containing tenofovir provided effective control of HIV-1 infection, with stable CD4+ cell counts and continued suppression of plasma HIV-1 level following the treatment switch from stavudine.Keywords
This publication has 5 references indexed in Scilit:
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Improvement of dyslipidemia in patients switching from stavudine to tenofovirAIDS, 2004
- Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavirAIDS, 2004
- Evolution of Lipid Abnormalities in Patients Switched From Stavudine- to Tenofovir-Containing RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Abacavir Substitution for Nucleoside Analogs in Patients With HIV LipoatrophyA Randomized TrialJAMA, 2002